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Objective: A syngeneic, acute, double lung transplant model in the rat was 
used to determine the impact of exogenous urfactant treatment on graft 
function after prolonged cold storage. Methods: The donor grafts were flush 
perfused, preserved for 16 hours, and then reperfused for 120 minutes. 
Untreated lungs served as controls (group I). In group II the recipient 
received a 200 mg/kg dose of surfactant (CuroSurf) before reperfusion. In 
groups I I I  and IV~ surfactant was administered before perfusion and 
harvesting (III, 20 mg/kg; IV, 200 mg/kg). Serial measurements of graft 
pulmonary vascular resistance, alveolar-arterial oxygen difference, and 
compliance were obtained. Final graft assessment included weight gain and 
histologic study. Results: Repeated-measures analysis of variance showed 
significant improvement of graft performance in respect o compliance, 
alveolar-arterial oxygen difference, and pulmonary- vascular esistance in 
donor surfaetant reatment group IV (200 mg/kg} in comparison with 
recipient reatment (group II) and untreated controls (group I). Reducing 
the donor surfactant supplementation from 200 mg/kg to 20 mg/kg (group 
lII) improved oxygenation and lung compliance as compared with un- 
treated controls. Grafts in groups I and I I  had significantly more weight 
gain after 2 hours of reperfusion. Recipient reatment resulted in signifi- 
cantly more pulmonary hemorrhage in histologic sections. Conclusion: 
Donor treatment with exogenous surfaetant is advantageous for preserva- 
tion of graft function after extended ischemia. Positive effects may be seen 
with as little as 20 mg/kg of exogenous surfactant given before donor organ 
perfusion. (J Thorac Cardiovase Surg 1997;113:1050-8) 
T he standard method of graft preservation in clinical lung transplantation consists of donor 
pretreatment with either prostaglandin E 1 or pros- 
taglandin 12, flush perfusion, and storage with Euro- 
Collins solution at 4 ° C. With this preservation 
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method, ischemic intervals up to 8 hours are pres- 
ently considered compatible with good postopera- 
tive graft function. However, graft dysfunction may 
still be encountered espite apparently adequate 
preservation. Therefore various alterations in the 
method of preservation have been recommended 
on the basis of experimental data. 1 Studies by 
Waldhausen, 2 Veldhuizen, 3 and their associates 
have shown severe alterations of pulmonary surfac- 
tant content and function resulting from ischemia 
and reperfusion. This phenomenon correlates with 
the absolute duration of ischemia 3'4 and may be 
caused by the degree of static inflation during 
storage,S, 6 surfactant deactivation through plasma 
proteins,7, s or ischemic damage to type II alveolar 9 
cells. Consequently a decrease in lung compliance, 
functional residual capacity, and oxygen uptake may 
be encountered uring reperfusion. 1° If graft func- 
tion is to be preserved after extended ischemia, 
surfactant depletion and dysfunction must be 
avoided. If this is not possible, surfactant replace- 
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ment may be an alternative approach. Experimental 
investigations have shown benefits from replace- 
ment therapy with exogenous urfactant immedi- 
ately before reperfusion. 11 
The following study was designed to test the 
hypothesis that timing of surfactant supplementa- 
tion is critical for amelioration of reperfusion injury 
after lung transplantation. An  additional aim was to 
test for a donor-response r lation with the amount 
of surfactant used for donor treatment. 
Material and methods 
Male Lewis rats (350 to 400 gin) were obtained from 
Charles River Laboratories, Salzfeld, Germany, and all 
animals received humane care in compliance with the 
"Principles of Laboratory Animal Care" formulated by 
the "National Society for Medical Research" and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
Publication No. 86-23, revised 1985). 
Experimental groups. The impact of exogenous surfac- 
tant treatment was evaluated in four experimental groups. 
The ischemic interval was limited to 16 hours in all groups. 
Untreated transplanted lungs served as controls (group I, 
n = 10; no surfactant therapy). Animals of group II (n = 
6) received a 200 mg/kg dose of exogenous urfactant 
(CuroSurf, Chiesa Farmaceutici, Parma, Italy) 15 minutes 
before reperfusion. In groups III (n = 10) and IV (n = 6), 
exogenous surfactant supplementation was added imme- 
diately after donor intubation as a bolus therapy into the 
donor trachea (group III, 20 mg/kg; group IV, 200 mg/kg). 
To determine the impact of timing the surfactant treat- 
ment, we compared groups I, II, and IV with each other. 
For dose-response analysis we compared groups III and 
IV. 
Experimental procedure. The model of acute in situ 
double lung transplantation i  the rat used in this exper- 
imental setting has been previously described in detail. 12 
After sedation, intubation, ventilation, and heparinization 
all lungs were flush perfused with a 60 ml/kg dose of 
low-potassium dextran solution 13 (LPD, Perfadex) at 4 ° C 
and at a perfusion pressure of 20 cm H20 during contin- 
ued ventilation. The lungs were stored with static inflation 
(26 cm H20 ) in low-potassium dextran solution at 4 ° C. 6 
After an ischemic interval of 16 hours, the graft pulmo- 
nary trunk and left atrium were connected to the left 
pulmonary artery and vein of a syngeneic recipient rat 
with the use of two custom-designed T-shaped stents, one 
of which was equipped with a built-in Doppler probe 
(H-2R probe, Transonic Systems, Inc., Ithaca, N.Y.). Both 
stents included side ports for blood retrieval and pressure 
measurements (Fig. 1). The graft trachea was intubated 
with a 13-gauge cannula and the graft was ventilated 
separately with a volume-controlled respirator (Harvard 
Rodent Ventilator model 683; Harvard Apparatus Co., 
Inc., S. Natick, Mass.) at a tidal volume of 5 ml, a 
respiratory rate of 45 to 65 breaths/min, and a positive 
end-expiratory pressure of 3 cm H20. The inspiratory 
oxygen concentration was selected at 1.0. After hepa- 
rinization of the recipient, graft reperfusion was initiated. 
The respiratory rate of the donor lung was adjusted 
according to analysis of blood gases in the left pulmonary 
vein, with a target carbon dioxide tension of 30 to 40 mm 
Hg. Fluid was replaced with either blood or crystalloid 
fluids introduced through the pulmonary artery stent to 
ensure a pulmonary arterial pressure of 20 mm Hg and a 
hematocrit value of 30% to 40%. The donor lung was kept 
moist by intermittent topical application of warm saline 
solution. The pH measured in the pulmonary venous 
blood gases was titrated with 8.5% sodium bicarbonate to 
achieve a pH of 7.25 to 7.5. 
Measurements. The observation period for each exper- 
iment was limited to 120 minutes with serial measure- 
ments beginning 5 minutes after removal of the pulmo- 
nary artery clamp and then repeated every 20 minutes. 
Each measurement included the following parameters: 
left pulmonary arterial and venous blood gas analysis, left 
pulmonary arterial and left atrial blood pressure (PAP 
and LAP), isolated onor lung blood flow, and donor lung 
function (compliance, resistance). Derived parameters 
included alveolar-arterial oxygen difference (millimeters 
of mercury) and pulmonary vascular esistance (millime- 
ters of mercury per milliliter per minute). The amount of 
intraalveolar edema was quantified after intratracheal 
suction before each measurement. At the end of the 
observation period the weight gain was determined (per- 
cent) and a histologic analysis performed. 
Histology. At the end of the observation period the 
graft was flushed with formalin through the pulmonary 
artery and the airways via the trachea. The graft was then 
stored in formalin, cut, and stained with hematoxylin and 
eosin. Evaluation was performed in a blinded, semiquan- 
titative fashion. The amount of interstitial edema, intraal- 
veolar edema, granulocyte infiltration, and pulmonary 
hemorrhage was scored on a scale of 1 to 4, with 1 being 
the least amount and 4 the maximum amount observed. 
Statistical analysis. Data were analyzed with the Sta- 
tistical Program of Social Sciences (SPSS for Windows 
Version 6.0.1, SPSS, Inc., Chicago, Ill.). All data are 
expressed as mean _+ standard error. Analysis of contin- 
uous data, such as compliance, resistance, alveolar-arte- 
rial oxygen difference, and pulmonary vascular esistance, 
was performed by repeated-measures analysis of variance 
(ANOVA). 14 The model used incorporated a fixed time 
effect, a fixed group effect, a time by group interaction 
effect, and a random animal effect. In addition, the change 
over time was statistically analyzed with this model. For 
multiple comparisons the Bonferroni adjustment was in- 
corporated. The group interaction effect will be reported 
only when found to be significant. Continuous data with- 
out repeated measurements, such as donor and recipient 
animals' weights, weight increase of graft, donor compli- 
ance, and animal survival, as well as nonparametric data, 
such as the histologic semiquantitative analysis, were 
compared with the Mann-Whitney test. 
Results 
Donors. Donor  and recipient rats were randomly 
assigned to the four groups (Table I). The mean 
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Fig. 1. Experimental setup of the acute double lung transplantation model. A donor lung is connected to 
a syngeneic recipient animal with two specially designed stents. The donor lung is ventilated separately. A 
pneumotachograph with analog/digital converters allows isolated determination f donor lung function. 
The analog/digital converter is connected to a computer for online data recording and display. The side 
ports of both stents are used for pressure measurement and blood retrieval for gas measurements. PAP, 
Pulmonary artery pressure; LAP, left atrial pressure. 
Table I 
Surfactant treatment 
Group I: Group II: Group III Group IV.." 
Control Recipient 200 mg/kg Donor 20 mg/kg Donor 200 mg/kg Statistics (Mann- Whitney teSt) 
Graft ischemia (hr) 16 16 16 16 
Donor lung compliance 68 _+ 45§ 64 _+ 3*t 79 ± 4*§ 82 _+ 4t~ *p < 0.05, tP  < 0.04 
(ml/cm H20) ~:p < 0.03, §p < 0.05 
Donor lung resistance 245 + 20 231 _+ 17 243 2 16 277 _+ 28 NS 
(cm H20/ml/sec) 
Donor weight (gin) 348 + 13 367 _+ 10 346 2 14 367 _+ 16 NS 
Recipient weight (gm) 353 _+ 22 374 _+ 8 347 2 32 370 _+ 25 NS 
Survival (rain) 116 _+ 13 113 +_ 4 120 + 0 120 _+ 0 NS 
Comparison ofnonserial measurements of donor and recipient animal weight, donor dynamic compliance and resistance b fore perfusion, and mean survival. 
Donor treatment with surfactant significantly increased the dynamic lung compliance ofthe graft. All test statistics were done with the Mann~Whitney t st. 
For explanation offootnote symbols, ee Statistics olumn (far right). 
total ischemic times were comparable in all groups, 
as were pretreatment pulmonary resistance. The 
pulmonary compliance was significantly better in the 
donor surfactant pretreatment groups (groups III 
and IV) after surfactant administration than in 
controls and in group II (Table I). 
Recipients. The average length of survival is de- 
picted in Table I. Timing of surfactant administra- 
tion did not significantly fiffect survival. Both donor 
treatment groups (III and IV) survived the 2-hour 
study period. During the experiment, pronounced 
amounts of edema were suctioned from the tracheal 
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Fig. 2. Dynamic pulmonary compliance measured in 20-minute intervals. Repeated-measures ANOVA 
comparison between group I (control group), group II (recipient reatment 200 mg/kg dose of surfactant), 
group III (donor treatment 20 mg/kg dose of surfactant), and group IV (donor treatment 200 mg/kg dose 
of surfactant) (ANOVA: group I vs group IV, p < 0.02; group II vs group IV, p < 0.04; group III vs group 
IV, p < 0.02). 
tube, mainly in group II, with a total of 22 _+ 2 ml 
for the entire reperfusion period. This was signif- 
icantly higher than in group I (5.7 + 1.3 ml; 
Mann-Whitney test: p < 0.001) and group IV 
(8.8 _+ 1.3 ml;p < 0.006). No significant difference 
was noted in the amount of edematous fluid 
retrieved in group III (4.4 +_ 0.8 ml) and group IV 
(see above). The weight increase of group II 
animals was substantially higher (125% + 46%) 
than that of group IV (78% _+ 35%; Mann- 
Whitney test: p < 0.05). 
Lung funct ion .  The pulmonary dynamic ompli- 
ance was significantly higher in group IV animals 
(donor treatment, 200 mg/kg) than in the recipient 
treatment group II (repeated-measures ANOVA: 
p < 0.04) or untreated animals (group I; repeated- 
measures ANOVA: p < 0.02). The increased 
amount of surfactant administered to group IV 
animals significantly improved ynamic ompliance 
when comparing with that of group III (donor 
treatment 20 mg/kg; repeated-measures ANOVA; 
p < 0.02). Fig. 2 shows a decline in compliance in 
groups II, III, and IV over the reperfusion period 
(repeated-measures ANOVA: p < 0.05; p < 0.001; 
p < 0.001, respectively). 
The differences among groups regarding airway 
resistance were similar to those obtained from dy- 
namic compliance measurements. For example, 60 
minutes after reperfusion the animals of group I had 
a resistance of 678 _+ 54 cm HzO/L per second 
versus 648 + 110 cm H20/L per second in group II 
and 307 _+ 12 cm H20/L per second in group IV. 
The repeated-measures ANOVA was p < 0.04 in 
group IV versus group I and p < 0.05 in group IV 
versus group II (Fig. 3). The airway resistance was 
significantly lower in 200 mg donor treatment than 
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Fig. 3. Resistance to pulmonary air flow measured in centimeters of water per liter per second. 
Repeated-measures ANOVA for group effect: group I versus group IV, p < 0.04; group II versus group IV, 
p < 0.05; group III versus group IV, p < 0.02. 
with 20 mg donor treatment (repeated-measures 
ANOVA: p < 0.02). 
The arterial-alveolar oxygen difference was se- 
verely impaired in untreated grafts (group I). The 
alveolar-arterial oxygen difference of group IV was 
significantly lower than that of all other groups 
(repeated-measures ANOVA to group I, p < 0.05; 
to group II, p < 0.02). Again, the increased ose of 
surfactant provided better oxygenation when com- 
pared with that of group III (repeated-measures 
ANOVA: p < 0.01). Fig. 4 shows a constant and 
significant increase of the alveolar-arterial oxygen 
difference in all groups (repeated-measures 
ANOVA to group I,p < 0.001; to group II, p < 0.04; 
to group III, p < 0.0001; to group IV, p < 0.003). 
Finally, the pulmonary vascular resistance was 
significantly lower after donor treatment with 200 
mg/kg than that in groups I and II (repeated- 
measures ANOVA: p < 0.05 and p < 0.04, respec- 
tively). The pulmonary vascular esistance in group 
III was not significantly different from that in 
group IV. Fig. 5 shows a significant decline in the 
pulmonary vascular esistance in groups II and IV 
(repeated-measures ANOVA:p < 0.04,p < 0.0006, 
respectively). 
Histology. The results of the blinded histologic 
semiquantitative analysis of the specimens from 
the four experimental groups are summarized in 
Table II. It is noteworthy that granulocyte infil- 
tration was practically negligible in all groups. 
Despite the significant differences in hemody- 
namic and lung function analysis, as well as weight 
increase, among the individual groups, the pro- 
nounced graft edema is not reflected in the two- 
dimensional histologic assessment. Only the de- 
gree of pulmonary hemorrhage was significantly 
increased in group II when compared with group 
IV (Mann-Whitney: p < 0.05). 
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Fig. 4. Comparison of alveolar-arterial oxygen difference. Donor treatment with exogenous surfactant 
with either 20 or 200 mg/kg improves graft function with respect to oxygenation (group I vs group IV, p < 
0.05; group II vs group IV, p < 0.02; group III vs group IV, p < 0.01). 
Discuss ion 
Ischemia-reperfusion njury is one of the main 
causes of early morbidity and mortality in clinical 
lung transplantation. Various factors have been 
made responsible for this severe postoperative com- 
plication, one of which is related to ischemia-in- 
duced surfactant dysfunction and depletion. Exper- 
imental studies by Andrade, 4 Veldhuizen, 3 and their 
colleagues have provided ample data that underline 
this observation. These changes are evident imme- 
diately after flush perfusion and increase in severity 
during storage. So far it seems that these alterations 
in the surfactant system cannot be avoided. There- 
fore various authors have introduced exogenous 
surfactant replacement therapy to lung transplanta- 
tion. In a 38-hour ischemia experiment by Novick 
and colleagues, I  the results after exogenous surfac- 
tant treatment were generally positive, but not al- 
ways persistent. Clinically, Striiber and coworkers 
used nebulized surfactant for a single patient with 
early signs of ischemia-reperfusion injury and were 
able to reverse the course and avoid further tissue 
damage. On the basis of the presently available data, 
it remains unclear whether donor or recipient re- 
placement therapy with exogenous urfactant can 
achieve the best results. 
According to the results obtained in the study 
presented here, exogenous surfactant replacement 
therapy in the donor before organ perfusion can 
significantly improve graft function after extended 
ischemia when compared with results in untreated 
controls or treatment of the donors lungs immedi- 
ately before implantation, referred to in this text as 
recipient treatment. The results are persistent and 
highly significant. Compared with untreated con- 
trois or the recipient reatment group, the donor 
treatment group (group IV) had increased pulmo- 
nary compliance, resistance, and oxygenation and 
decreased pulmonary vascular esistance. The posi- 
tive effect of donor surfactant treatment is dose- 
1056 Hausen et al. 
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Fig. 5. The vascular esistance to pulmonary blood flow measured in millimeters of mercury per minute 
per milliliter is markedly elevated in group I and group II. Pulmonary vascular esistance changed 
significantly over time in group I (repeated-measures ANOVA: p < 0.05), group II (p < 0.04), and group 
IV (p < 0.0006). Repeated-measures ANOVA for group effect: group I versus group IV, p < 0.05; group 
II versus group IV, p < 0.04; group III versus group IV, p < 0.3. 
Table II 
Sulfactant treatment 
Group L Group II: Group HI." Group II/.: 
Control Recipient 200 mg/kg Donor 20 mg/kg Donor 200 mg/kg Statistics (Mann-Whitney test) 
Granulocyte infi ltration 1 + 0 1 _+ 0 1 _+ 0 1 ± 0 NS 
Pulmonary hemorrhage 1.8 ± 0.8 2.3 _+ 1.0 1.6 ± 0.8 1.3 ± 0.5 p < 0.05 
(II vs IV) 
Interst it ial  edema 1.3 ± 0.5 1.4 + 0.5 1.3 ± 0.4 1.3 ± 0.5 NS 
Intraalveolar edema 2.0 + 0.9 1.8 +_ 0.4 1.9 _+ 0.5 1.8 ± 0,4 NS 
Semiquantitative histologic assessment of lung specimens after the end of reperfusion. Pulmonary hemorrhage was significantly more pronounced in group 
II compared to group IV (Mann-Whitney test, p < 0.05). Score: 1 = no, 2 = mild, 3 = moderate, 4 = severe. 
dependent, with gradual improvements of graft 
function. Positive effects regarding preservation of 
graft function may be seen with as little as 20 mg/kg 
of surfactant given to the donor before organ per- 
fusion. Recipient treatment was advantageous only 
in comparison with the untreated controls with 
respect to improvements of the alveolar-arterial 
oxygen difference. 
Despite these striking hemodynamic and oxygen- 
ation differences between individual treatment reg- 
imens, the histologie changes were only modest. 
Perhaps longer reperfusion periods to show distinct 
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changes or more sophisticated methods of analysis 
are required for this model. 
Potential mechanisms of surfactant-related lung 
dysfunction have been recently addressed by Novick 
and coworkers. 16 Alveolar type II cells play a mul- 
tifaceted role in determining alveolar integrity un- 
der physiologic onditions and during evolving lung 
injury. From surfactant replacement s udies in pa- 
tients with an adult respiratory distress yndrome, it
is known that exogenous surfactant instillation leads 
to recruitment of atelectatic alveoli, as well as 
increased distention of existing air spaces. Both 
increase the effective lung volume, lower the 
arterial-alveolar oxygen gradient, and decrease 
arteriovenous shunting. 17 As a result of the Euler- 
Liljestrand reflex, previously atelectatic and malper- 
fused lung tissue is then uniformly and effectively 
perfused. This is extremely important for the phase 
of organ flush perfusion with chilled preservation 
solutions, because it ensures an even distribution of 
the protective media throughout the entire lung. 18 
Improved preservation may be one reason that the 
donor treatment in this study was so much more 
effective than the recipient treatment after ischemia. 
According to studies by Erasmus and col- 
leagues, 19 the surfactant pool is inversely propor- 
tional to time of cold ischemia. Because of the 
remaining activity of phospholipase, the valuable 
endogenous urfactant pool may be significantly 
reduced before the beginning of reperfusion. Con- 
sequently, this leads to atelectasis 3 and inhomoge- 
neous reperfusion] s Anaerobic metabolism can 
trigger the complement cascade and result in addi- 
tional tissue damage. The administration of surfac- 
rant immediately before reperfusion may then be 
too late to improve overall lung function owing to 
irreversible lung damage. Also, the accumulation of
plasma proteins during ischemia through damaged 
cell membranes can immediately deactivate the en- 
dogenous and the exogenous surfactant pool. 8 Pro- 
phylactic and preventive donor treatment limits 
membrane damage and complement activation and 
thus preserves the exogenous and endogenous sur- 
factant pool. 
The adult human and animal surfactant pool size is 
in the range of 3 to 15 mg/kg. Exogenous urfactant 
administration results in an uptake of more than 60% 
of the surfactant dose into the alveolar type II cells of 
normal rabbit lungs, a° This results in a significant net 
increase of the overall surfactant secretion for at least 
10 hours after instillation. 2~ Surfactant reatment 
therefore has a long-lasting effect. 
In most animal models the donor lung must be 
considered perfectly normal. In the clinical situation 
the negative impact of brain death, hemodynamic 
instability, infection, trauma, and extended ventila- 
tion with possible barotrauma can result in surfac- 
tant depletion and therefore significant dysfunction 
of the donor lung. 22 This may underline the impor- 
tance of early exogenous surfactant treatment. 
Exogenous surfactant supplementation is pres- 
ently costly and most likely not available as a routine 
procedure for a donor lung in clinical transplanta- 
tion. This study has shown a hemodynamic and 
oxygenation benefit with as little as 20 mg/kg of 
surfactant given as a bolus to the donor intratrache- 
ally. This form of treatment should be considered 
for donor lungs after extended ventilation periods 
before harvesting. Critical and borderline pulmo- 
nary grafts with atelectasis or edema may benefit 
from this treatment and thus be rendered suitable 
for transplantation. Future studies should assess 
endogenous urfactant phospholipid quantity and 
composition i  donor lungs to help distinguish those 
grafts that would benefit most from surfactant sup- 
plementation. In addition, it will be important o 
sort out which mechanism is most predominant in
catising altered surfactant function after lung trans- 
plantation. 
To conclude, this study has shown a significant 
benefit on graft function after donor versus recipient 
treatment with exogenous urfactant. After an ex- 
tended ischemic interval of 16 hours, the pulmonary 
function of the transplanted graft was well pre- 
served. In addition, donor surfactant treatment is
dose-dependent. Positive effects may be seen with as 
little as 20 mg/kg of exogenous urfactant given 
before donor organ perfusion. 
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Discussion 
Dr. Richard J. Novick iLondon. Ontario. Canadaj. In a 
recent article we have shown exactly the same thing in a 
canine model - - that  the donors must be treated with 
surfactant o get an optimal result. That is one of the 
themes that is emerging. 
It is also important o look at the types of surfactant. 
The large aggregates are the metabolic precursors of the 
small aggregates: the large aggregates are surface active 
and are effective: the small aggregates do not reduce 
surface tension. Did you have a chance to look at the 
small-to-large aggregate ratio in lung lavages from the 
transplanted animals? 
Finally, concerning cost. the standard dose that has 
been used in adult respiratory distress yndrome and lung 
injury studies is 100 mg/kg. If one expects to transplant 
one lung graft, 50 mg/kg may well be enough; as you have 
shown, even 20 mg/kg provides some benefit. I think the 
cost of surfactant will decline with time, and it may be 
affordable if it is shown to be effective when administered 
as a single shot to donors. 
Dr. Hausen. Thank you for your comments. In these 
experiments we have not looked at the lavage as we have 
added surfactant. We thought hat doing so would confuse 
our results. In other previously performed experiments, 
however, we have looked at the small-to-large aggregate 
ratio and seen significant differences that actually made us 
think about this type of treatment, We chose 200 mg from 
the literature. Concerning trials with adult respiratory 
distress syndrome, and even using 20 mg, the costs may 
amount to around $10.000 per patient: 50 mg would be 
$25.000. I do not know whether the American system can 
rectify these costs. We. in Germany, could not 
